Unfractionated versus low-molecular-weight heparin in the treatment of venous thromboembolism

Abstract

Low-molecular-weight heparin (LMWH) fractions are prepared from standard unfractionated heparin (UFH) and are thus similar to UFH in many aspects. The main advantages of this new class of antithrombotic agents as compared with UFH are: (1) an improved bioavail-ability and a prolonged half-life, which alleviate cumbersome laboratory monitoring and may permit one single daily subcutaneous injection; and (2) an improved efficacy-to-safety ratio, with less bleeding despite similar or improved efficacy. For these reasons, LMWH is progressively replacing UFH for preventing postoperative thromboembolism and for treating established deep vein thrombosis and pulmonary embolism. However, the effects of the new compounds need to be evaluated carefully in some other indications (arterial thrombosis, unstable angina, or myocardial infarction - the latter also in conjunction with thrombolytic treatment) before they can generally replace UFH in pharmacotherapy.

Keywords

anticoagulation low-molecular-weight heparin unfractionated heparin

References

Choay J , Petitou M , Lormeau JC , Sinay P , Casu B , Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-Factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-499.

Rosenberg RD , Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-6505.

Kakkar VV , Murray WJG. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thromboembolism: a co-operative study. Br J Surg 1985; 72: 786-791.

Hemker HC , Béguin S. Mechanism of action of heparin and low-molecular-weight heparins. In: Bounameaux H ed. Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases. New York: Marcel Dekker, 1994: 21-42.

Lecompte T , Luo SK , Stieltjes N , Lecrubier C , Samama MM. Thrombocytopenia associated with low-molecular-weight heparin (letter). Lancet 1991; 338: 1217-1217.

Warkentin TE , Kelton JG. Interactions of heparins with platelets, including heparin-induced thrombocytopenia. In: Bounameaux H ed. Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases. New York: Marcel Dekker, 1994: 75-128.

Warkentin TE , Levine MN , Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.

Monreal M , Lafoz E , Olive A , Del Rio L , Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contra-indications to coumarin. Thromb Haemost 1994; 71: 7-11.

Handeland GF , Abildgaard U , Holm HA , Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 1990; 30: 107-112.

10.

Alhenc-Gelas M , Jestin-Le Guernic C , Vitoux JF , Kher A , Aiach M , Fiessinger JN. Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin in the treatment of deep vein thrombosis. Fragmin Study Group. Thromb Haemost 1994; 71: 698-702.

11.

Boneu B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost 1994; 72: 330-334.

12.

Leizorovicz A , Haugh MC , Chapuis FR , Samama MM , Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305: 13-20.

13.

Nurmohamed MT , Rosendaal FR , Büller HR et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-156.

14.

Kakkar VV , Cohen AT , Edmonson RA et al on behalf of the Thromboprophylaxis Collaborative Group. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-265.

15.

Bachmann F , Leyvraz PF. Low-molecular-weight heparins after orthopedic surgery. In: Bounameaux H ed. Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases. New York: Marcel Dekker, 1994: 187-212.

16.

Menzin J , Colditz GA , Regan MM , Richner RE , Oster G. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995; 155: 757-764.

17.

Huber O , Bounameaux H , Borst F , Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg 1992; 127: 310-313.

18.

Sarasin FP , Bounameaux H. Cost-effectiveness of prolonged postoperative prophylactic anticoagulation following hospital discharge. Arch Surg 1996; 131: 694-697.

19.

Planes A , Vochelle N , Darmon JY , Fagola M , Bellaud M , Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-228.

20.

Bergqvist D , Benoni G , Björgell O et al. Low-molecular-weight heparin (Enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.

21.

Sarasin FP , Bounameaux H. Antithrombotic strategy after total hip replacement: a cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis. Arch Intern Med 1996; 156: 1661-1668.

22.

Leizorovicz A , Simonneau G , Decousus H , Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994; 309: 299-304.

23.

Lensing AWA , Prins MH , Davidson BL , Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995; 155: 601-607.

24.

Teo CP , Lim HL , Kueh YK. Cost effectiveness and ease of administration of low molecular weight heparin in deep vein thrombosis. Thromb Haemost 1994; 72: 328-329.

25.

Hull RD , Raskob GE , Rosenbloom D et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med 1997; 157: 289-294.

26.

Koopman MMW , Prandoni P , Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-687.

27.

Levine MN , Gent M , Hirsh J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-681.

28.

Hull RD , Raskob GE , Pineo GF et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-982.

29.

Lindmarker P , Holmstrom M , Granqvist S , Johnsson H , Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72: 186-190.

30.

Charbonnier BA , Fiessinger JN , Sixma JJ et al. Comparison of a once daily versus a twice daily subcutaneous nadroparin calcium regimens in the treatment of deep vein thrombosis. On behalf of the FRAXODI Group. Circulation 1996; 94(suppl I): I-742 (abstract).

31.

Théry C , Simonneau G , Meyer G et al. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. Circulation 1992; 85: 1380-1389.

32.

Simonneau G , Sors H , Charbonnier B et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-669.

33.

Nurmohamed MT , Büller HR , ten Cate JW. Low molecular weight heparins in extracorporeal circuits. In: Bounameaux H ed. Low-molecular weight heparins in prophylaxis and therapy of thromboembolic diseases. New York: Marcel Dekker, 1994: 247-271.

34.

Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group . Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-568.

35.

Kay R , Wong KS , Yu YL et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333: 1588-1593.

36.

Maternal and Neonatal Haemostasis Working Party of the Haemostasis and Thrombosis Task Force . Guidelines on the prevention, investigation and management of thrombosis associated with pregnancy. J Clin Pathol 1993; 46: 489-496.

37.

Forestier F , Daffos F , Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy. Study by direct fetal blood sampling under ultrasound. Thromb Res 1984; 34: 557-560.

38.

Forestier F , Daffos F , Rainaut M , Toulemonde F. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy (letter). Thromb Haemost 1987; 57: 234-234.

39.

Hunt BJ , Doughty HA , Majumdar G et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 77: 39-43.

40.

Boda Z , Laszlo P , Rejto L et al. Low molecular weight heparin as thromboprophylaxis in familial thrombophilia during the whole period of pregnancy (letter). Thromb Haemost 1996; 76: 128-128.